Volume 2, Issue 1 (February 2017)                   JNFS 2017, 2(1): 87-95 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Talaei B, Mozaffari-Khosravi H, Bahreini S. The Effect of Ginger on Blood Lipid and Lipoproteins in Patients with Type 2 Diabetes: A Double-Blind Randomized Clinical Controlled Trial. JNFS. 2017; 2 (1) :87-95
URL: http://jnfs.ssu.ac.ir/article-1-33-en.html
PhD Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract:   (713 Views)

Background: Preliminary clinical trials showed that ginger improved lipid profile in type 2 diabetes patients (T2D). This trial was carried out to determine the effect of ginger on blood lipid and lipoproteins in T2D. Methods: this is a randomized, double-blind, placebo-controlled trial on 88 T2D conducted in. The patients were randomly divided into two groups of ginger (GG) and placebo (PG), the GG consumed daily 3 one-gram capsules containing ginger powder whereas the other group received capsules of the same color and number as GG but containing cellulose microcrystalline, both after taking meals and for eight weeks. Serum total cholesterol (TC), triglycerides (TG), HDL-c, LDL-c, Apo B100 and Apo A1 were measured at the baseline and the end of trial. Results: Out of 88 patients who participated in the trial, 81 of them accomplished it. No significant changes were observed in mean of TC, TG, HDL-c, and Apo B100 within and between the groups. Serum LDL-c and LDL-c/HDL-c ratio were decreased significantly in the GG (P = 0.03, P = 0.028) at the end of trail but they were not significantly different between the two groups. Serum Apo A1 was increased significantly in the GG (P < 0.05) and PG (P < 0.05) at the end of trial but it was not significantly different between the two groups. Conclusions: This study indicated that daily consumption of 3 g of ginger powder in capsules for 8 weeks by T2D leads to lowering of LDL-c, LDL-c/HDL-c ratio, and Apo A1. Therefore, consumption of this supplementation is appropriate for this patients

Full-Text [PDF 465 kb]   (270 Downloads)    
Type of article: orginal article | Subject: public specific
Received: 2016/05/10 | Accepted: 2016/08/4 | Published: 2017/02/1

1. Al-Amin ZM, Thomson M, Al-Qattan KK, Peltonen-Shalaby R & Ali M 2006.
2. Anti-diabetic and hypolipidaemic properties of ginger (Zingiber officinale) in streptozotocin-induced diabetic rats. Br J Nutr. 96 (4):
3. 660-666.
4. Ali BH, Blunden G, Tanira MO & Nemmar A 2008. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol. 46 (2): 409-420.
5. Alizadeh-Navaei R, et al. 2008. Investigation of the effect of ginger on the lipid levels. A double blind controlled clinical trial. Saudi Med J. 29 (9): 1280-1284.
6. Andallu B, Radhika B & Suryakantham V 2003. Effect of aswagandha, ginger and mulberry on hyperglycemia and hyperlipidemia. Plant Foods for Human Nutrition.(58): 1-7.
7. American Diabetes Association 2010. Diagnosis and classification of diabetes mellitus. Diabetes Care. 37 Suppl 1: S81-90.
8. Bhandari U, Kanojia R & Pillai KK 2005. Effect of ethanolic extract of Zingiber officinale on dyslipidaemia in diabetic rats. J Ethnopharmacol. 97 (2): 227-230.
9. Bordia A, Verma S & Srivastava K 1997. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins, leukotrienes and essential fatty acids. 56 (5): 379-384.
10. Chrubasik S, Pittler M & Roufogalis B 2005. Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. Phytomedicine. 12 (9): 684-701.
11. ElRokh E-SM, Yassin NA, El-Shenawy SM & Ibrahim BM 2010. Antihypercholesterolaemic effect of ginger rhizome (Zingiber officinale) in rats. Inflammopharmacology. 18 (6): 309-315.
12. Esteghamati A, et al. 2008. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National Survey of Risk Factors for Non-Communicable Diseases of Iran. Diabetes Care. 31 (1): 96-98.
13. Fink RI, Wallace P, Brechtel G & Olefsky JM 1992. Evidence that glucose transport is rate-limiting for in vivo glucose uptake. Metabolism. 41 (8): 897-902.
14. Fukuyama N, et al. 2008. Validation of the Friedewald Equation for Evaluation of Plasma LDL-Cholesterol. J Clin Biochem Nutr. 43 (1): 1-5.
15. Gilani AH & Rahman AU 2005. Trends in ethnopharmocology. J Ethnopharmacol. 100 (1-2): 43-49.
16. Grzanna R, Lindmark L & Frondoza CG 2005. Ginger-an herbal medicinal product with broad anti-inflammatory actions. J Med Food. 8 (2): 125-132.
17. Kamal R & Aleem S 2009. Clinical evaluation of the efficacy of a combination of zanjabeel (Zingiber officinale) and amla (Emblica officinalis) in hyperlipidaemia. Indian J trad. know. 8 (3): 413-416.
18. McGarry JD 2002. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 51 (1): 7-18.
19. Paranjpe P, Patki P & Patwardhan B 1990. Ayurvedic treatment of obesity: a randomised double-blind, placebo-controlled clinical trial. J Ethnopharmacol. 29 (1): 1-11.
20. Parillo M & Riccardi G 2004. Diet composition and the risk of type 2 diabetes: epidemiological and clinical evidence. Br J Nutr. 92 (1): 7-19.
21. Randle PJ, Garland PB, Hales CN & Newsholme EA 1963. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1 (7285): 785-789.
22. Roden M, et al. 1996. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 97 (12): 2859-2865.
23. Seidell JC 2000. Obesity, insulin resistance and diabetes--a worldwide epidemic. Br J Nutr. 83 Suppl 1: S5-8.
24. Shirdel Z, Mirbadalzadeh H & Madani H 2009. Anti-diabetic and anti lipidemic properties of ginger in comparison glibenclamide in alloxan-diabetes rat. Iran J Diab Lipid Disorders.(9): 7-15.
25. Singh AB, SN Akanksha S, Maurya R & . 2009. Anti-hyperglycaemic, lipid lowering and anti-oxidant properties of [6]-gingerol in db/db mice. Int. J. of Med & Med Sci. 12: 536-544.
26. Srivastava KC 1984. Aqueous extracts of onion, garlic and ginger inhibit platelet aggregation and alter arachidonic acid metabolism. Biomed Biochim Acta. 43 (8-9): S335-346.
27. Srivastava KC & Mustafa T 1992. Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Med Hypotheses. 39 (4): 342-348.
28. Surh YJ, Lee E & Lee JM 1998. Chemoprotective properties of some pungent ingredients present in red pepper and ginger. Mutat Res. 402 (1-2): 259-267.
29. Tripathi S, Maier KG, Bruch D & Kittur DS 2007. Effect of 6-gingerol on pro-inflammatory cytokine production and costimulatory molecule expression in murine peritoneal macrophages. J Surg Res. 138 (2): 209-213.
30. Verma SK, Singh M, Jain P & Bordia A 2004. Protective effect of ginger, Zingiber officinale Rosc on experimental atherosclerosis in rabbits. Indian J Exp Biol. 42 (7): 736-738.
31. Wang WH & Wang ZM 2005. [Studies of commonly used traditional medicine-ginger]. Zhongguo Zhong Yao Za Zhi. 30 (20): 1569-1573.
32. White B 2007. Ginger: an overview. Am Fam Physician. 75 (11): 1689-1691.
33. Wild S, Roglic G, Green A, Sicree R & King H 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 27 (5): 1047-1053.

Add your comments about this article : Your username or Email:
Write the security code in the box

© 2015 All Rights Reserved | Journal of Nutrition and Food Security

Designed & Developed by : Yektaweb